Home   Logon   Mobile Site   Research and Commentary   About Us   Call 1.800.621.1675 or Email Us       Follow Us: 

Search by Ticker, Keyword or CUSIP       


SMid Biotechnology Portfolio, Series 1
Ticker Symbol: FHTUNX

Ticker Company Name Initial
ACAD ACADIA Pharmaceuticals Inc. 2.50% $31.05
XLRN Acceleron Pharma Inc. 2.49% 42.55
AGIO Agios Pharmaceuticals, Inc. 2.49% 77.53
AIMT Aimmune Therapeutics, Inc. 2.50% 34.96
ALNY Alnylam Pharmaceuticals, Inc. 2.49% 120.83
FOLD Amicus Therapeutics, Inc. 2.50% 14.84
ANAB AnaptysBio, Inc. 2.49% 121.03
ARNA Arena Pharmaceuticals, Inc. 2.50% 40.52
ARGX argenx SE 2.51% 78.15
ARRY Array BioPharma Inc. 2.50% 17.19
AVXS AveXis, Inc. 2.48% 113.47
BMRN BioMarin Pharmaceutical Inc. 2.48% 83.85
BLUE bluebird bio, Inc. 2.51% 205.45
BPMC Blueprint Medicines Corporation 2.48% 81.84
CBPO China Biologic Products Holdings, Inc. 2.52% 83.23
CLVS Clovis Oncology, Inc. 2.49% 53.71
CRSP CRISPR Therapeutics AG 2.49% 41.61
EDIT Editas Medicine, Inc. 2.51% 33.28
EBS Emergent BioSolutions Inc. 2.50% 48.62
EXAS Exact Sciences Corporation 2.50% 48.01
EXEL Exelixis, Inc. 2.50% 28.83
FGEN FibroGen, Inc. 2.50% 54.60
GLPG Galapagos N.V. 2.52% 115.28
GBT Global Blood Therapeutics, Inc. 2.50% 65.90
HALO Halozyme Therapeutics, Inc. 2.50% 18.48
HRTX Heron Therapeutics, Inc. 2.51% 22.50
IMMU Immunomedics, Inc. 2.51% 16.22
LGND Ligand Pharmaceuticals Inc. 2.50% 155.51
LOXO Loxo Oncology, Inc. 2.48% 104.33
MDXG MiMedx Group, Inc. 2.50% 8.75
NBIX Neurocrine Biosciences, Inc. 2.50% 84.58
PTLA Portola Pharmaceuticals, Inc. 2.51% 48.22
PBYI Puma Biotechnology, Inc. 2.50% 67.05
RGEN Repligen Corporation 2.49% 31.76
SAGE Sage Therapeutics, Inc. 2.52% 163.18
SRPT Sarepta Therapeutics, Inc. 2.51% 62.87
SGEN Seattle Genetics, Inc. 2.51% 54.16
ONCE Spark Therapeutics, Inc. 2.49% 50.23
SPPI Spectrum Pharmaceuticals, Inc. 2.50% 20.30
UTHR United Therapeutics Corporation 2.52% 134.96

* As of the close of business on 2/20/18.
Market values are for reference only and are not indicative of your individual cost basis.

Not FDIC Insured • Not Bank Guaranteed • May Lose Value

Portfolio Summary
Initial Date of Deposit 2/21/2018
Initial Public Offering Price $10.00 per Unit
Portfolio Ending Date 5/22/2019
Cash CUSIP 30307B664
Reinvestment CUSIP 30307B672
Fee Account Cash CUSIP 30307B680
Fee Account Reinvestment CUSIP 30307B698

Sales Charges (based on a $10 public offering price)
Standard Accounts
Transactional Sales Charges: Initial: 0.00%
  Deferred: 1.35%
Creation and Development Fee:   0.50%
Maximum Sales Charge:   1.85%

The deferred sales charge will be deducted in three monthly installments commencing 6/20/18.

When the public offering price is less than or equal to $10.00 per unit, there will be no initial sales charge. If the price exceeds $10.00 per unit, you will pay an initial sales charge.

Fee/Wrap Accounts
Maximum Sales Charge: 0.50%

The maximum sales charge for investors in fee accounts consists of the creation and development fee. Investors in fee accounts are not assessed any transactional sales charges. Standard accounts sales charges apply to units purchased as an ineligible asset.

The creation and development fee is a charge of $.050 per unit collected at the end of the initial offering period. If the price you pay exceeds $10.00 per unit, the creation and development fee will be less than 0.50%; if the price you pay is less than $10.00 per unit, the creation and development fee will exceed 0.50%.

In addition to the sales charges listed, UITs are subject to annual operating expenses and organization costs.

You should carefully consider the portfolio's investment objectives, risks, and charges and expenses before investing. Contact your financial advisor or call First Trust Portfolios, L.P. at 1.800.621.1675 to request a prospectus, which contains this and other information about the portfolio. Read it carefully before you invest.

Risk Considerations:
An investment in this unmanaged unit investment trust should be made with an understanding of the risks involved with owning common stocks, such as an economic recession and the possible deterioration of either the financial condition of the issuers of the equity securities or the general condition of the stock market.

You should be aware that the portfolio is concentrated in biotechnology and pharmaceutical companies in the health care sector which involves additional risks, including limited diversification. The companies engaged in the biotechnology and pharmaceutical industries are subject to fierce competition, substantial research and development costs, governmental regulations, pricing constraints, and their products and services may be subject to rapid obsolescence. Biotechnology and pharmaceutical stocks have experienced extreme price and volume fluctuations that are often unrelated to their operating performance. In addition, implementation of the Health Care and Education Affordability Reconciliation Act of 2010 continues to have significant implications for companies in the health care sector.

An investment in a portfolio containing small-cap and mid-cap companies is subject to additional risks, as the share prices of smallcap companies and certain mid-cap companies are often more volatile than those of larger companies due to several factors, including limited trading volumes, products, financial resources, management inexperience and less publicly available information.

An investment in a portfolio containing equity securities of foreign issuers is subject to additional risks, including currency fluctuations, political risks, withholding, the lack of adequate financial information, and exchange control restrictions impacting foreign issuers.

Although this portfolio terminates in approximately 15 months, the strategy is long-term. Investors should consider their ability to pursue investing in successive portfolios, if available. There may be tax consequences unless units are purchased in an IRA or other qualified plan.

The value of the securities held by the trust may be subject to steep declines or increased volatility due to changes in performance or perception of the issuers.

Fund Cusip Information
30307B664 (Cash)
30307B672 (Reinvest)
30307B680 (Cash-Fee)
30307B698 (Reinvest-Fee)
Printer Friendly Page Printer Friendly Page
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA and the Internal Revenue Code. First Trust has no knowledge of and has not been provided any information regarding any investor. Financial advisors must determine whether particular investments are appropriate for their clients. First Trust believes the financial advisor is a fiduciary, is capable of evaluating investment risks independently and is responsible for exercising independent judgment with respect to its retirement plan clients.
First Trust Portfolios L.P.  Member SIPC and FINRA.
First Trust Advisors L.P.
Home |  Important Legal Information |  Privacy Policy |  Business Continuity Plan |  FINRA BrokerCheck
Copyright © 2018 All rights reserved.